Reaction
Triple Negative Breast Cancer reporting signals
As of the last recalculation, Triple Negative Breast Cancer appears in 621 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is DEXAMETHASONE SODIUM PHOSPHATE (PRR 50.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dexamethasone Sodium Phosphate | 15 | 50.7 | 50.8 |
| Atezolizumab | 45 | 41.8 | 41.8 |
| Paclitaxel | 75 | 28.7 | 28.8 |
| Paclitaxel (Aibumin-Bound) | 60 | 27.0 | 27.0 |
| Diroximel Fumarate | 8 | 22.8 | 22.8 |
| Docetaxel Anhydrous | 37 | 19.5 | 19.5 |
| Docetaxel | 37 | 19.5 | 19.5 |
| Olaparib | 11 | 17.9 | 17.9 |
| Gemcitabine Hydrochloride | 22 | 14.4 | 14.4 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 13.4 | 13.4 |
| Gemcitabine | 15 | 13.1 | 13.1 |
| Pegfilgrastim | 35 | 12.5 | 12.5 |